ASP5878 is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It is being studied as a selective inhibitor targeting specific kinases involved in cancer cell proliferation and survival. By inhibiting these kinases, ASP5878 aims to disrupt signaling pathways that promote tumor growth, making it a promising candidate for treating certain types of cancers. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other anticancer therapies. Preclinical and clinical trials are essential to determine its role in future cancer treatment regimens.